share_log

Phio Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Phio Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Phio Pharmaceuticals | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/15 05:54

Moomoo AI 已提取核心信息

Phio Pharmaceuticals reported Q3 2024 net loss of $1.52 million, compared to $2.78 million in Q3 2023, as research and development expenses decreased 64% to $644,000. The company ended the quarter with cash of $5.39 million, down from $8.49 million at year-end 2023.The significant reduction in R&D expenses reflects the company's transition from research to product development, including headcount reduction and termination of the AgonOx collaboration agreement in May 2024. The company is now focused on its Phase 1b clinical trial of PH-762 for skin cancer treatment, which has shown positive safety data in initial patient cohorts.Management expects current cash reserves to fund operations into Q2 2025 but notes substantial doubt about continuing as a going concern without additional funding. The company is evaluating financing options while advancing its lead candidate PH-762, which has demonstrated promising early clinical results with no serious adverse events reported in patients treated to date.
Phio Pharmaceuticals reported Q3 2024 net loss of $1.52 million, compared to $2.78 million in Q3 2023, as research and development expenses decreased 64% to $644,000. The company ended the quarter with cash of $5.39 million, down from $8.49 million at year-end 2023.The significant reduction in R&D expenses reflects the company's transition from research to product development, including headcount reduction and termination of the AgonOx collaboration agreement in May 2024. The company is now focused on its Phase 1b clinical trial of PH-762 for skin cancer treatment, which has shown positive safety data in initial patient cohorts.Management expects current cash reserves to fund operations into Q2 2025 but notes substantial doubt about continuing as a going concern without additional funding. The company is evaluating financing options while advancing its lead candidate PH-762, which has demonstrated promising early clinical results with no serious adverse events reported in patients treated to date.
Phio Pharmaceuticals报告2024年第三季度净亏损152万美元，较2023年第三季度的278万美元有所减少，因为研究和开发费用减少了64%，降至644,000美元。公司在本季度结束时拥有现金539万美元，低于2023年年末的849万美元。研发费用的显著减少反映了公司从研究转向产品开发的过渡，包括减少员工人数和在2024年5月终止与AgonOx的合作协议。公司目前专注于PH-762治疗皮肤癌的10亿阶段临床试验，初期患者队列显示出积极的安全性数据。管理层预计当前现金储备将能够支持运营至2025年第二季度，但指出在没有额外资金的情况下继续作为持续经营存在重大怀疑。公司正在评估融资期权，同时推进其领先候选药物PH-762，该药物在至今治疗的患者中表现出有前景的早期临床结果，且未报告严重不良事件。
Phio Pharmaceuticals报告2024年第三季度净亏损152万美元，较2023年第三季度的278万美元有所减少，因为研究和开发费用减少了64%，降至644,000美元。公司在本季度结束时拥有现金539万美元，低于2023年年末的849万美元。研发费用的显著减少反映了公司从研究转向产品开发的过渡，包括减少员工人数和在2024年5月终止与AgonOx的合作协议。公司目前专注于PH-762治疗皮肤癌的10亿阶段临床试验，初期患者队列显示出积极的安全性数据。管理层预计当前现金储备将能够支持运营至2025年第二季度，但指出在没有额外资金的情况下继续作为持续经营存在重大怀疑。公司正在评估融资期权，同时推进其领先候选药物PH-762，该药物在至今治疗的患者中表现出有前景的早期临床结果，且未报告严重不良事件。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！